There were 635 press releases posted in the last 24 hours and 151,499 in the last 365 days.

Results from an ongoing phase II study of isolated thoracic perfusion with chemofiltration for pleural mesothelioma

Scheme of Isolated Thoracic Perfusion with Chemofiltration (ITP-F)

Favorable results from an ongoing study of regional chemotherapy for pleural mesothelioma presented at the 59th Congress of the German Society for Pneumology

BURGHAUSEN, GERMANY, April 11, 2018 /EINPresswire.com/ -- Medias Klinikum GmbH & Co KG, a private hospital specialized in surgical oncology, focusing on the treatment of primary and metastatic solid tumors, announces that the results from an ongoing phase II study of regional chemotherapy in terms of isolated thoracic perfusion with chemofiltration (ITP-F) for malignant pleural mesothelioma, published in the peer-reviewed journal OncoTargets and Therapy, have been presented at the 59th Congress of the German Society for Pneumology and Respiratory Medicine (DGP) in Dresden, Germany. The study, Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma, was conducted by Professor Dr. Karl R. Aigner, one of the world’s most experienced experts in the field of regional chemotherapy, and his group. In 1981, he developed the technique of isolated liver perfusion and was the first physician worldwide performing this method in humans using a heart-lung machine.

The data of this study was published in OncoTargets and Therapy in June 19, 2017.

Commenting on the announcement, Professor Dr. Karl R. Aigner, Head of the Department of Surgical Oncology at Medias Klinikum, said, “Malignant pleural mesothelioma is a therapy-resistant disease for which there is no cure. Even in stage I and II, surgical intervention is no curative procedure – even if major operations are performed – in a multimodal setting to minimize tumor burden. Multimodal approaches (bi- and trimodality) are currently being investigated in this group of patients, but up to now, no substantial survival benefit could be achieved with these debilitating treatments. Looking at the existing data on various multimodal therapies, there is still a lack of therapies when conventional surgery, chemotherapy, and radiotherapy fail and result in progressive-disease (PD). This gap, following this phase II study, could be filled by the method of intra-arterial isolated perfusion with con¬comitant chemofiltration (ITP-F). The preliminary results of the study presented at the 59th Congress of the German Society for Pneumology and Respiratory Medicine this year, showed that ITP-F for patients with advanced pleural mesothelioma, progressive after stan-dard therapies, is an effective and well-tolerated treatment modality, with encouraging survival data beyond the survival rates seen with other therapies in this patient population.
As such, the approach of isolated thoracic perfusion warrants further investigation. We are confident that a phase III study could provide the evidence necessary to adopt this therapy modality into future treatment programs.

About Medias Klinikum, Department of Surgical Oncology
Medias Klinikum is a private clinic located in Burghausen (Bavaria), Germany specialized in regional chemotherapy (RCT), a targeted treatment modality for primary and metastatic tumors that is highly concentrated, regional, and less toxic. We have more than 35 years of expertise in this special field of surgical oncology. Prof. Dr. med. Aigner, the medical director of the clinic, is one of the world’s most experienced experts in this treatment method. He has given numerous lectures on RCT and performed guest operations in the most renowned institutions in the USA, Japan, China, Israel, Egypt, Australia and a number of other countries. In 1981, Professor Aigner developed a technique for performing the first isolated liver perfusion in humans using a heart-lung machine, and over subsequent years a variety of additional surgical procedures and specialized catheters for isolated therapy of organs and parts of the body, including the treatment of pancreatic carcinoma.

Public Relations
Medias Klinikum GmbH & Co KG
+49867791600
email us here